INS and Hyperglycemia: Inhibitors of this enzyme may cause beta mobile pressure to decrease (thus decreasing postmeal hyperglycemia) and the production of glucagon-like peptide-1 (GLP-1) to increase (thus increasing insulin secretion) as a result [41, 42].